Pivotal single dose 3-way bioequivalence study of ELI 202 under fasting and fed conditions in volunteers.
Latest Information Update: 26 May 2014
At a glance
- Drugs ELI 202 (Primary)
- Indications Opioid-related disorders; Pain
- Focus Pharmacokinetics; Registrational
- Sponsors Elite Pharmaceuticals
Most Recent Events
- 26 May 2014 New trial record